Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Wilmott

Showing results (71-80 of 162) with videos related to

Pageof 17
Sort By:
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 13, 2016
Plasma cells in primary melanoma. Prognostic significance and possible role of IgAFrancesca M Bosisio, James S Wilmott, Nathalie Volders, et al.
Cancer|July 29, 2015
Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitorsAlexander M Menzies, James S Wilmott, Martin Drummond, et al.
International Journal of Cancer|December 7, 2017
HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanomaStuart J Gallagher, Dilini Gunatilake, Kimberley A Beaumont, et al.
Oncotarget|November 4, 2014
Noxa upregulation by oncogenic activation of MEK/ERK through CREB promotes autophagy in human melanoma cellsYi Lun Liu, Fritz Lai, James S Wilmott, et al.
Pigment Cell & Melanoma Research|May 12, 2016
Multiparameter analysis of naevi and primary melanomas identifies a subset of naevi with elevated markers of transformationCarly Fox, Duncan Lambie, James S Wilmott, et al.
Oncoimmunology|February 1, 2020
Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patientsTuba N Gide, Ines P Silva, Camelia Quek, et al.
Bioinformatics (Oxford, England)|September 15, 2018
bcGST-an interactive bias-correction method to identify over-represented gene-sets in boutique arraysKevin Y X Wang, Alexander M Menzies, Ines P Silva, et al.
BMC Cancer|June 3, 2018
Differences in LC3B expression and prognostic implications in oropharyngeal and oral cavity squamous cell carcinoma patientsKenneth Lai, Slade Matthews, James S Wilmott, et al.
Oncogene|May 31, 2018
Melanoma protective antitumor immunity activated by catalytic DNAHong Cai, Eun-Ae Cho, Yue Li, et al.
Journal for Immunotherapy of Cancer|October 21, 2023
Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapiesNurudeen A Adegoke, Tuba N Gide, Yizhe Mao, et al.
Pageof 17

Showing results (71-80 of 162) with videos related to

Sort By:
Pageof 17
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 13, 2016
Plasma cells in primary melanoma. Prognostic significance and possible role of IgAFrancesca M Bosisio, James S Wilmott, Nathalie Volders, et al.
Cancer|July 29, 2015
Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitorsAlexander M Menzies, James S Wilmott, Martin Drummond, et al.
International Journal of Cancer|December 7, 2017
HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanomaStuart J Gallagher, Dilini Gunatilake, Kimberley A Beaumont, et al.
Oncotarget|November 4, 2014
Noxa upregulation by oncogenic activation of MEK/ERK through CREB promotes autophagy in human melanoma cellsYi Lun Liu, Fritz Lai, James S Wilmott, et al.
Pigment Cell & Melanoma Research|May 12, 2016
Multiparameter analysis of naevi and primary melanomas identifies a subset of naevi with elevated markers of transformationCarly Fox, Duncan Lambie, James S Wilmott, et al.
Oncoimmunology|February 1, 2020
Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patientsTuba N Gide, Ines P Silva, Camelia Quek, et al.
Bioinformatics (Oxford, England)|September 15, 2018
bcGST-an interactive bias-correction method to identify over-represented gene-sets in boutique arraysKevin Y X Wang, Alexander M Menzies, Ines P Silva, et al.
BMC Cancer|June 3, 2018
Differences in LC3B expression and prognostic implications in oropharyngeal and oral cavity squamous cell carcinoma patientsKenneth Lai, Slade Matthews, James S Wilmott, et al.
Oncogene|May 31, 2018
Melanoma protective antitumor immunity activated by catalytic DNAHong Cai, Eun-Ae Cho, Yue Li, et al.
Journal for Immunotherapy of Cancer|October 21, 2023
Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapiesNurudeen A Adegoke, Tuba N Gide, Yizhe Mao, et al.
Pageof 17